FDA Issues Complete Response Letter to Galderma for RelabotulinumtoxinA Over Manufacturing Observations
Key Insights
The FDA issued a Complete Response Letter for Galderma's RelabotulinumtoxinA BLA, citing manufacturing site observations and analytical method optimization needs, with no safety or efficacy deficiencies identified.
RelabotulinumtoxinA (Relfydess) is a ready-to-use liquid neuromodulator already approved in 33 markets and launched in over 20 countries, including Europe, the Middle East, Asia, and Australia.
The manufacturing facility has completed 10 inspections by global regulatory authorities since 2022, and Galderma is implementing corrective and preventive actions to address the FDA's observations.
Galderma has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for RelabotulinumtoxinA, a next-generation botulinum toxin candidate branded as Relfydess. The CRL relates exclusively to observations made during a manufacturing site inspection and requests for analytical method optimization. Critically, the FDA raised no deficiencies related to the safety or efficacy portions of the filing, and no new clinical studies have been requested.
The FDA conducted a Pre-License Inspection (PLI) of Galderma's manufacturing facility as part of the standard BLA review process. In response, Galderma stated it is implementing corrective and preventive actions to address the observations and will maintain open dialogue with the agency to resolve the outstanding issues. "Advancing RelabotulinumtoxinA in the U.S. remains a top priority," the company noted, though the timeline for resubmission and any subsequent FDA review cycle remains undefined.
A Differentiated Neuromodulator with Global Momentum
RelabotulinumtoxinA is a complex-free, ready-to-use liquid botulinum toxin type A neuromodulator developed using Galderma's proprietary PEARL Technology. Unlike conventional botulinum toxin products that require reconstitution prior to injection, Relfydess is designed to simplify dosing and aims to provide consistent treatment outcomes. The molecule acts by cleaving SNAP-25 (search), a SNARE complex protein at the neuromuscular junction, thereby blocking acetylcholine release and inducing temporary muscle relaxation.
Clinical data indicate that some patients experience early onset of effect, with improvements sustained for several months. The BLA covers aesthetic indications consistent with those approved in international markets.
Importantly, the FDA's comments do not affect approvals or launches in other international markets. Relfydess is already approved in 33 markets and has been launched in more than 20, including Europe, the Middle East, Asia, and Australia. Early launch feedback from healthcare professionals has been described as encouraging, and regulatory filings in additional territories remain on track.
Manufacturing Track Record
Galderma emphasized that since 2022, the manufacturing site in question has completed 10 inspections by key regulatory authorities from around the world, forming the basis for Relfydess launches in more than 20 markets. This track record may support a relatively efficient resolution process with the FDA, though the precise nature of the manufacturing observations has not been publicly disclosed.
US Market Implications
The CRL delays what would have been a significant commercial entry into the US injectable aesthetics market, where Relfydess would represent a differentiated offering as the first ready-to-use liquid formulation. The current US landscape is dominated by AbbVie (search)'s onabotulinumtoxinA (Botox Cosmetic), with incobotulinumtoxinA (Xeomin, Merz Aesthetics (search)) and prabotulinumtoxinA (Jeuveau, Evolus) also approved and marketed. None of these competitors offer a liquid, ready-to-use format.
For Galderma, the US entry of Relfydess has been described as a strategic priority and a key driver of its injectable aesthetics growth ambitions. The delay comes as the company continues its broader ambition to become a leading dermatology powerhouse across injectable aesthetics, skincare, and therapeutic dermatology, following EQT's full exit from Galderma via a block trade in March 2026, which completed the company's transition to full public market ownership.